GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eidos Therapeutics Inc (FRA:6MX) » Definitions » Other Gross PPE

Eidos Therapeutics (FRA:6MX) Other Gross PPE : €3.99 Mil (As of Sep. 2020)


View and export this data going back to 2018. Start your Free Trial

What is Eidos Therapeutics Other Gross PPE?

Eidos Therapeutics's Other Gross PPE for the quarter that ended in Sep. 2020 was €3.99 Mil.

Eidos Therapeutics's quarterly Other Gross PPE declined from Mar. 2020 (€4.54 Mil) to Jun. 2020 (€4.35 Mil) and declined from Jun. 2020 (€4.35 Mil) to Sep. 2020 (€3.99 Mil).

Eidos Therapeutics's annual Other Gross PPE increased from Dec. 2017 (€0.07 Mil) to Dec. 2018 (€0.08 Mil) and increased from Dec. 2018 (€0.08 Mil) to Dec. 2019 (€4.61 Mil).


Eidos Therapeutics Other Gross PPE Historical Data

The historical data trend for Eidos Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eidos Therapeutics Other Gross PPE Chart

Eidos Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19
Other Gross PPE
- 0.07 0.08 4.61

Eidos Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.70 4.61 4.54 4.35 3.99

Eidos Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Eidos Therapeutics (FRA:6MX) Business Description

Traded in Other Exchanges
N/A
Address
101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104
Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.

Eidos Therapeutics (FRA:6MX) Headlines

No Headlines